May 23 (Reuters) - Advisers to the U.S. Food and Drug

Administration on Thursday recommended for the approval of

Guardant Health's ( GH ) blood test to detect a cancer that

begins in the colon or rectum.

The panel voted seven-to-two in favor of benefits

outweighing risks when using the test called Shield for

colorectal cancer.

(Reporting by Puyaan Singh and Leroy Leo in Bengaluru; Editing

by Arun Koyyur)